Ozonides for treating or preventing virus infections
Inventors
Boger, Ravit • Vennerstrom, Jonathan
Assignees
Johns Hopkins University • University of Nebraska Medical Center UNMC • University of Nebraska System
Publication Number
US-11246854-B2
Publication Date
2022-02-15
Expiration Date
2038-05-15
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described are methods of treating or preventing a virus in a subject comprising administering ozonides to the subject.
Core Innovation
The invention is directed to methods of treating or preventing a virus in a subject, specifically by administering ozonides to the subject. Ozonides, particularly compounds of Formula I, are tested for their antiviral activities, notably against members of the herpesvirus family such as human cytomegalovirus (HCMV), varicella zoster (VZV), HSV1, HSV2, HHV6, and HHV8. The compounds can be administered in various pharmaceutical forms, including as pharmaceutically acceptable salts, solvates, or stereoisomers.
The background addresses a significant need for new CMV therapies due to toxicities and resistance associated with currently approved systemic anti-CMV drugs that target viral DNA polymerase. Artemisinins show promise for their anti-HCMV activities but have limitations, such as a short half-life. Using ozonides, a new category of bioactive peroxides designed by simplifying artemisinin’s structure, the invention overcomes these shortcomings.
Experimental data included in the invention show that ozonides such as OZ418 are effective in inhibiting replication of both wild-type and ganciclovir-resistant CMV strains in vitro and in vivo. The invention covers methods of using these compounds to inhibit herpesvirus replication in biological samples, including cells, blood, tissue, or whole subjects, and their inclusion in pharmaceutical compositions for administration to subjects at risk of or suffering from viral infection.
Claims Coverage
There is 1 independent claim in the patent, each focusing on different aspects of inhibiting virus replication using ozonides.
Method of inhibiting virus replication in vitro using ozonides
This inventive feature covers: - Providing a biological sample containing a replicating virus. - Applying a compound of Formula I (as described and exemplified in the specification) to the sample. - The method results in inhibition of virus replication in the biological sample.
The claim coverage centers on the use of compounds of Formula I, specifically ozonides, to inhibit replication of viruses in biological samples. The core inventive feature is the application of these specific compounds for antiviral activity in vitro.
Stated Advantages
Ozonides such as OZ418 show improved efficacy in inhibiting replication of both wild-type and drug-resistant cytomegalovirus strains, overcoming resistance observed with current drugs.
Ozonides have an extended half-life compared to artesunate, allowing for more effective and potentially less frequent dosing for continuous virus suppression.
Ozonides can inhibit virus replication in multiple types of biological samples and are effective in both in vitro and in vivo settings.
Pharmaceutical compositions containing ozonides can be administered via multiple routes, including oral, topical, and parenteral, providing flexibility in treatment.
Documented Applications
Treatment or prevention of virus infection in a subject through administration of ozonides.
Inhibition of virus replication in vitro in biological samples such as blood, cells, or tissue.
Treatment of herpesvirus infections, including cytomegalovirus (CMV), varicella zoster (VZV), HSV1, HSV2, HHV6, and HHV8.
Use of pharmaceutical compositions containing ozonides for administration to subjects at risk of or suffering from herpesvirus infection.
Interested in licensing this patent?